Fabry disease deserves consideration in females with compatible findings or an affected relative. Describing someone simply as a carrier can obscure clinically significant disease. An enzyme result also needs careful interpretation: alpha-galactosidase A activity alone is an inadequate diagnostic strategy in females. The practical task is to bring biochemical evidence, genetic analysis and organ assessment together without asking any one result to answer every question.
Recognize the range of disease
Fabry disease involves pathogenic variants in GLA, which encodes the lysosomal enzyme alpha-galactosidase A. Reduced enzyme function impairs the breakdown of globotriaosylceramide, allowing this lipid to accumulate in cells. The kidneys, heart and nervous system can be affected. MedlinePlus Genetics describes both classic and later-onset presentations.
Clinical clues include pain in the hands and feet, reduced sweating, angiokeratomas, corneal changes and gastrointestinal symptoms. Later-onset disease may predominantly involve one organ system. These findings provide a reason to investigate; their presence does not by itself establish Fabry disease.
The condition is X-linked, but females with one altered copy of GLA can have substantial illness, including kidney disease, cardiac complications and stroke. Onset and severity vary. A relatively mild presentation in a female relative should therefore be interpreted as that person’s clinical history, rather than a reliable forecast for another family member. MedlinePlus Genetics
Understand what biochemical testing contributes
A 2020 diagnostic study evaluated 11,948 females suspected of having Fabry disease using a combined biochemical and genetic approach. Adding dried-blood-spot lyso-Gb3 measurement to enzyme activity improved detection compared with enzyme activity alone. Lyso-Gb3 is a related lipid biomarker; it contributes information that the enzyme measurement does not capture by itself. Balendran and colleagues
When both biochemical measurements were abnormal, the reported positive predictive value was 97%. When only one was abnormal, elevated lyso-Gb3 was more informative than low enzyme activity. These findings support combined assessment, while also showing why an isolated low enzyme result requires interpretation.
The study involved a selected population with suspected disease. Its predictive values should not be transferred directly to unselected populations or treated as universal laboratory thresholds. Nor does improved detection establish how well a biomarker predicts future organ damage. Diagnostic performance and prognosis are separate questions. 2020 diagnostic study
Keep diagnosis and disease burden separate
A 2025 expert opinion recommends basing diagnosis in females on genetic analysis and evaluating potentially affected organ systems. This creates two linked clinical questions: does the genetic evidence establish Fabry disease, and what manifestations are present now? A molecular finding cannot replace the second assessment. Tuttolomondo and colleagues
A useful clinical summary keeps three elements explicit:
- Diagnostic evidence: the genetic interpretation and supporting biochemical findings.
- Current manifestations: symptoms and documented organ involvement.
- Remaining uncertainty: unresolved findings and the limits of predicting progression.
This structure helps prevent a biomarker value from becoming shorthand for overall disease severity. It also makes clear which conclusions are established and which require further assessment.
Separate clinical practice from evidence gaps
The 2025 publication combined a survey of nine Italian Fabry centres with discussion among eleven specialists. The survey represented 227 females, most identified through family screening. It described monitoring and treatment practices, including enzyme replacement therapy; it was not a randomized comparison establishing the best treatment threshold. 2025 expert opinion
The authors support individualized monitoring and treatment decisions informed by symptoms, organ damage and additional clinical evidence. Their recommendations provide a specialist framework, while their call for more research acknowledges continuing uncertainty. Observing that treatment is used in practice does not establish its benefit for every asymptomatic female or identify an optimal starting point.
For clinicians, the central discipline is to retain these distinctions throughout follow-up: biochemical measurements support assessment, genetic evidence addresses diagnosis, and longitudinal clinical evaluation addresses disease burden. Decisions about surveillance and disease-specific treatment require specialist interpretation of the whole picture.